Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Serra R, Giunta EF, Schepisi G, Brighi N, Montanari D, Lolli C, Bleve S, Piras M, Palmieri G, Scartozzi M, Paliogiannis P, De Giorgi U. Serra R, et al. Among authors: montanari d. Expert Rev Anticancer Ther. 2024 Dec 25:1-7. doi: 10.1080/14737140.2024.2445152. Online ahead of print. Expert Rev Anticancer Ther. 2024. PMID: 39716888 Review.
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives.
Merloni F, Palleschi M, Gianni C, Sirico M, Serra R, Casadei C, Sarti S, Cecconetto L, Di Menna G, Mariotti M, Maltoni R, Montanari D, Romeo A, De Giorgi U. Merloni F, et al. Among authors: montanari d. Clin Exp Metastasis. 2024 Dec;41(6):863-875. doi: 10.1007/s10585-024-10312-3. Epub 2024 Sep 23. Clin Exp Metastasis. 2024. PMID: 39312051 Free PMC article. Review.
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.
Gasperoni L, Giunta EF, Montanari D, Masini C, De Giorgi U. Gasperoni L, et al. Among authors: montanari d. Expert Opin Drug Metab Toxicol. 2024 Jun;20(6):491-502. doi: 10.1080/17425255.2024.2353749. Epub 2024 May 22. Expert Opin Drug Metab Toxicol. 2024. PMID: 38778707 Free article. Review.
Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.
Monti M, Prochowski Iamurri A, Bianchini D, Gallio C, Esposito L, Montanari D, Ruscelli S, Molinari C, Foca F, Passardi A, Vittimberga G, Morgagni P, Frassineti GL. Monti M, et al. Among authors: montanari d. Nutrients. 2023 Aug 17;15(16):3604. doi: 10.3390/nu15163604. Nutrients. 2023. PMID: 37630794 Free PMC article.
Post COVID-19 irritable bowel syndrome.
Marasco G, Cremon C, Barbaro MR, Cacciari G, Falangone F, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ, Koc ES, Sirin G, Calıskan AR, Bengi G, Alıs EE, Lukic S, Trajkovska M, Hod K, Dumitrascu D, Pietrangelo A, Corradini E, Simren M, Sjölund J, Tornkvist N, Ghoshal UC, Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, Danese S, Portincasa P, Di Sabatino A, Maggio M, Philippou E, Lee YY, Salvi D, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; GI-COVID19 study group. Marasco G, et al. Gut. 2022 Dec 9:gutjnl-2022-328483. doi: 10.1136/gutjnl-2022-328483. Online ahead of print. Gut. 2022. PMID: 36591612
68 results